Truist cuts National Health Investors stock price target on lower FFO estimates

Truist cut its National Health Investors (NHI) price target to $80 from $81 while keeping a Buy rating, citing a $0.07/share second-quarter 2026 FFO model miss (with half tied to a CFO transition and deferred tax expense). The firm still highlights fundamentals support: a 5.2% dividend yield and a low-levered balance sheet (debt-to-equity 0.81). Operationally, NHI posted adjusted EPS of $1.15 vs $0.87 expected, but revenue fell short at $68.9M vs $71.52M, even as it raised the quarterly dividend by $0.02 to $0.94.

Analysis

The near-term winner is NHI’s equity base, but only if management can recycle sale proceeds into higher-yielding assets faster than the market discounts the earnings quality. The real second-order effect is on comparable healthcare REITs: cleaner balance sheets and external growth capacity should be rewarded, while heavier SNF exposure and higher leverage names could lag as investors separate recurring FFO from one-time asset-sale gains. In other words, the market is likely to pay up for optionality only if it shows up in run-rate FAD, not GAAP optics.

The key risk is that the current setup is more a capital-allocation story than an operating inflection. If rates back up or cap rates widen, the spread on redeployed capital compresses and the multiple expansion thesis fades quickly; if labor costs or occupancy wobble, the move toward operating exposure can raise earnings volatility rather than reduce it. The likely catalyst window is 1-3 months around the next update on how much of the sale proceeds are actually accretive versus sitting in low-return cash.

Consensus may be missing that a higher dividend alone does not make this a defensive REIT if normalized FFO is flat-to-down and the portfolio mix is becoming more cyclical. The market may overrate the balance-sheet strength while underweighting the risk that the business shifts from bond proxy to operating healthcare beta. Falsifier: if post-sale FAD does not reaccelerate by the next two quarters, the stock can de-rate back toward a yield-only valuation despite the balance sheet.

Key Decisions for Investors

• Prefer a patient long NHI entry only on weakness, not into strength; the setup is worth about 1 turn of multiple expansion only if management shows reinvestment accretion within 1-3 months.
• Relative-value idea: long NHI / short VNQ as a narrow healthcare-capital-allocation expression if you expect balance-sheet quality and asset recycling to outperform broader REIT duration exposure.
• If seeking a more direct sector pair, long NHI / short OHI looks cleaner than a directional long on the group, since NHI’s lower leverage gives it more flexibility if financing conditions tighten.
• Avoid using the dividend hike as a standalone bull case; if normalized FFO trends down again next quarter, fade rallies above the current implied fair-value range.